• Corpus ID: 30217035

Rational Design of Combinations for the Treatment of Advanced Cancer

@article{Komiya2016RationalDO,
  title={Rational Design of Combinations for the Treatment of Advanced Cancer},
  author={Takefumi Komiya},
  journal={Cancer clinical trials},
  year={2016},
  volume={1},
  pages={122}
}
  • T. Komiya
  • Published 11 November 2016
  • Medicine
  • Cancer clinical trials
Despite our enormous effort and progress in medicine, cancer remains a top health issue worldwide. According to recent statistics, more than eight million people annually succumb to the disease in the world [1]. It is clear that we must work much harder in order to eliminate this disease in the next several decades. We have a hope, however, that can encourage us to do so and move forward: cancer immunotherapy. Systemic immunotherapy for the treatment of cancer has been investigated for many… 
No Paper Link Available
1 Citations
Background Citations
1

One Citation

Types of Cancer and Surgery in Rats (Rattus norvegicus)
TLDR
The tumor suppressor gene (p53) will helps to supress the cancer genes in humans along with in animals, called as “Peto's paradox”.

References

SHOWING 1-10 OF 21 REFERENCES
Role of IL-2 in cancer immunotherapy
TLDR
The present review will focus on the key biological features of IL-2, current applications, limitations, and future directions ofIL-2 in cancer immunotherapy.
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
TLDR
Treatment efficacy was associated with a higher number of mutations in the tumors, and a tumor-specific T cell response paralleled tumor regression in one patient, suggesting that the genomic landscape of lung cancers shapes response to anti–PD-1 therapy.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
TLDR
Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
TLDR
Nivolumab was associated with even greater efficacy than docetaxel across all end points in subgroups defined according to prespecified levels of tumor-membrane expression (≥1, ≥5%, and ≥10%) of the PD-1 ligand.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
TLDR
The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer and immune responses to the immunizing antigen were observed in patients who received sipuleUcel- T.
Nivolumab in previously untreated melanoma without BRAF mutation.
TLDR
Nivolumab was associated with significant improvements in overall survival and progression-free survival, as compared with dacarbazine, among previously untreated patients who had metastatic melanoma without a BRAF mutation.
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
TLDR
Gefitinib in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced NSCLC did not have improved efficacy over gemcitABine and cascplatin alone, and the reasons for this remain obscure and require further preclinical testing.
PD-1 blockade in tumors with mismatch repair deficiency.
  • J. UramHao Wang L. Diaz
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2015
TLDR
MM status predicts clinical benefit of immune checkpoint blockade with pembrolizumab, and high total somatic mutation loads were associated with PFS.
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
TLDR
This large, placebo-controlled trial confirmed the favorable gefitinib safety profile observed in phase I and II monotherapy trials and showed no added benefit in survival, time to progression, response rate (TTP), or RR compared with standard chemotherapy alone.
...
...